HER2-Directed Therapies in NSCLC: Navigating Clinical Insights, Integration Challenges, and Access Considerations : Episode 11
Opinion
Video
Real-World Outcomes in HER2-Positive NSCLC
Key Takeaways
- Real-world outcomes for HER2-positive NSCLC differ from clinical trials due to diverse patient populations and treatment settings.
- Clinical trials involve selected patients, while real-world settings include those with comorbidities and varying performance statuses.
Dr Heymach real-world outcomes versus clinical trials for HER2-positive NSCLC and the management of common adverse events associated with HER2-directed therapies.
Video content above is prompted by the following:
- How do real-world patient outcomes for patients with HER 2 positive NSCLC compare to those seen in clinical trials?
- What are the most common treatment-related adverse events observed with HER2-directed therapies, and how are they managed?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Videos
Related Content
